Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib (LOU064) vs placebo in chronic spontaneous urticaria
CTR20213430Phase 3Completed
- Sponsor
- Not applicable
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of remibrutinib in chronic idiopathic urticaria (CIU), sponsored by Not applicable. Started Dec 2021; status: completed.
02
Drugs
remibrutinib
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20213430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213430.